UCLA Radiation Therapy Advances at ASTRO 2025
- Here's a summary of the noteworthy presentations by UCLA faculty at the ASTRO (American Society for Radiation Oncology) meeting:
- Key Recognition: A UCLA physician has been named a 2025 fellow of ASTRO, recognizing remarkable contributions to radiation oncology, cancer research, and patient care.
- Overall Theme: UCLA's research focuses on making cancer treatment safer, more precise, and more effective through emerging radiation therapies and imaging technologies.
UCLA Radiation Oncology Highlights from ASTRO 2024
Here’s a summary of the noteworthy presentations by UCLA faculty at the ASTRO (American Society for Radiation Oncology) meeting:
Key Recognition: A UCLA physician has been named a 2025 fellow of ASTRO, recognizing remarkable contributions to radiation oncology, cancer research, and patient care.
Overall Theme: UCLA’s research focuses on making cancer treatment safer, more precise, and more effective through emerging radiation therapies and imaging technologies.
Presentation Highlights:
* Abstract 148: SCIMITAR Trial – Prostate Cancer After Surgery: Four-year results show that SBRT after prostate surgery resulted in no signs of cancer returning in 62% of patients, with rare local recurrences, and comparable outcomes to conventional radiation. (Presented Sunday, Sept. 28 at 5:05pm PDT in Room 24 - dr. Jesus Juarez Casillas)
* Abstract 253: 5DCT – Improved Lung Tumor Imaging: 5DCT,a new CT imaging technique,provides more accurate scans for patients with irregular breathing compared to conventional 4DCT. It allows for better tumor definition and radiation planning. (Presented Monday, Sept. 29 at 3:10pm PDT in Room 155/157 – Dr. Daniel Low)
* Abstract 1005: MRI-guided Prostate SBRT – Adaptive Dose Painting: A study comparing standard MRI-guided SBRT to an adaptive dose-painted approach found that the adaptive approach led to higher acute side effects (urinary and bowel symptoms) without a corresponding improvement in patient-reported quality of life. (Presented Monday, Sept.29 at 8:30am PDT in Room 307/308 – Dr. Travis Courtney)
* Abstract 1003: MIRAGE Trial – Sexual Function After Prostate SBRT: Analysis of the MIRAGE trial showed that despite using MRI guidance to protect nerves, nearly one-third of men in both CT-guided and MRI-guided SBRT groups experienced impacts to sexual function. (Presented by Dr. Jonathan Massachi)
Source: Data provided by dr. Michael Steinberg,professor and chair of radiation oncology at UCLA.